home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Structural Insight Into A Parkinson's Disease Drug Target

  November, 10 2001 3:41
your information resource in human molecular genetics
Parkinson's disease (PD) is a progressive disorder of the central nervous system affecting more than 1 million people in the United States. PD is caused by the degeneration of dopamine-producing cells in the brain. Since dopamine itself cannot pass through the blood-brain barrier, the standard treatment for PD is administration of levodopa, which can reach the brain where it is converted to dopamine. A problem with this compound is that it can also be converted to dopamine in the bloodstream, leading to unwanted side effects. One way to mitigate this problem is to administer inhibitors of DOPA decarboxylase, the enzyme that converts levodopa to dopamine in the blood.

In the November issue of Nature Structural Biology (Vol. 8, No. 11, pages 963-967), Peter Burhard of the M. E. Muller Institute for Structural Biology at the University of Basel, Switzerland and his collaborators describe the structure of DOPA decarboxylase with carbiDOPA, an inhibitor used in Parkinson's disease treatment. The structure reveals how this drug binds its target enzyme and suggests ways to design inhibitors that bind more tightly and more specifically, possibly leading to better treatments for Parkinson's and other neurological diseases.

Author Contact:

Peter Burkhard
Biozentrum der Univ. Basel
M.E. Mueller Institute for Structural Biology
Klingelbergstrasse 70
CH-4056 Basel
Telephone: 41 41 61 267 20 91
Fax : 41 61 267 21 09
email: peter.burkhard@unibas.ch

(C) Nature Structural Biology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.